MediLexicon Logo
MediLexicon Logo
Abbreviations        Abbrev Definitions        Dictionary        ICD Codes        Equipment        Hospitals        Drugs        More..

REBETRON (TM) Combination Therapy

Company: Schering-Plough
Approval Status: Approved June 1998
Treatment for: hepatitis C
Areas: Immune System

| General Information |

General Information

Schering-Plough Corporation announced that the Food and Drug Administration (FDA) has approved the combination use of REBETOL (TM) (ribavirin, USP) Capsules and INTRON A (R) (interferon alfa-2b, recombinant) Injection, to be marketed as REBETRON (TM) combination therapy, for the treatment of chronic hepatitis C in patients with compensated liver disease who have relapsed following alpha interferon therapy. Prior to REBETRON (RM) combination therapy, the only drugs approved in the US for treating hepatitis C had been alpha interferons.

< back to top

REBETRON Drug Information

The Rebetron drug information shown above is licensed from Thomson CenterWatch. The information provided here is for general educational purposes only and does not constitute medical or pharmaceutical advice which should be sought from qualified medical and pharmaceutical advisers.

MediLexicon International Ltd Logo

Privacy Policy   |    Disclaimer   |    Contact / Feedback

MediLexicon International Ltd
Bexhill-on-Sea, UK
MediLexicon International Ltd © 2004-2016 All rights reserved.